Medications like Ozempic, Wegovy, and Saxenda are well-known for their weight-loss effects, but there’s more to these injections than meets the eye.
Initially intended for treating type 2 diabetes, GLP-1 agonists have revealed surprising benefits for heart, brain, liver, and kidney health. And now, they might even help reduce migraines, as indicated by a recent study.
In a pilot trial involving 31 participants with high BMI and frequent migraines, those given a daily injection of the GLP-1 agonist liraglutide reported a significant drop in headache frequency. After 12 weeks, their migraine days each month decreased from an average of 19.8 to about 10.7, which is nearly a 50% reduction.
Interestingly, factors like weight loss, age, sex, and concurrent medications didn’t seem to change the results.
“Our findings indicate that liraglutide might be effective for chronic migraines in obese patients, independent of weight loss,” the study authors from the University of Naples mentioned.
“This implies that the way liraglutide works to prevent migraines might not rely solely on its metabolic effects…”
More extensive studies with larger groups and control comparisons are necessary to confirm these findings. Nonetheless, medications like liraglutide and possibly the longer-acting cousin semaglutide could offer a new approach for treating migraines.
Migraines affect around 14 to 15 percent of the world’s population, yet the existing medications available often don’t work for everyone.
“Many patients still have unmet needs, especially when standard preventive medications fail,” noted neurologist Simone Braca and her team.
Participants in this pilot study had migraines that did not respond to other treatments, highlighting liraglutide’s effectiveness where many other drugs had failed.
GLP-1 agonists help regulate blood sugar and curb appetite by mimicking a natural hormone known as glucagon-like peptide-1, which the body releases after meals. This is why they are particularly effective for managing type 2 diabetes and weight issues.
However, GLP-1 receptors are present in various tissues and organs throughout the body. It makes sense that liraglutide and similar medications could have a broader impact beyond just the pancreas. Still, researchers are working to understand the full extent of these effects and whether they are beneficial or detrimental.
Recent studies have indicated that liraglutide and other GLP-1 agonists significantly lower intracranial pressure in the brain, which is speculated to trigger migraines.
In animal models, these medications have also been shown to effectively suppress migraine occurrences.
While this current pilot trial was relatively small, it did not explore the mechanisms behind liraglutide’s potential migraine relief, nor did it assess changes in intracranial pressure among the subjects.
That said, Braca and her colleagues believe that reduced pressure in the skull might contribute to the observed decrease in migraines. Recent animal studies have demonstrated that GLP-1 agonists can decrease fluid levels in the central nervous system, ultimately lowering intracranial pressure.
“These results lay the groundwork for larger trials aimed at further examining the role of GLP-1 receptor agonists in treating migraines,” concluded Braca and her research team.
The study was published in Headache.
